PHM Announces Execution of Letter of Intent (LOI) to Acquire Another Large Regional Business in Tennessee With $20 Million in Revenue and $4 Million in Adjusted EBITDA

LOS ANGELES, CALIFORNIA--(Marketwired - March 16, 2015) -

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.

Patient Home Monitoring (PHM) (TSX VENTURE:PHM), a profitable company with annualized revenues exceeding $55 million focused on rolling-up annuity-based healthcare service companies in the U.S. and Canada, announced it has executed a non-binding Letter of Intent (LOI) to acquire a company in Tennessee with unaudited approximate annualized revenues of $20,000,000 and Adjusted EBITDA of $4,000,000⁽¹⁾.

PHM's Chairman and executive team will hold a conference call scheduled for 1 pm EST, Wednesday, March 18, 2015.

PHM also provided updated details on the cancellation of the small $2.25 million annual revenue Georgia business LOI.

The Tennessee Letter of Intent (LOI)

The Tennessee business is a large, regionally-focused company offering home-based medical equipment and services for patients with chronic pulmonary conditions. The business services over 40,000 active patients. After close, PHM plans to start immediately offering cardiology and mobility services to these patients with an eye toward increasing organic revenues and profits of the business.

According to the LOI, PHM will acquire 100% of the outstanding shares of the business for cash for a total consideration of $14,348,000. PHM has sufficient cash on the balance sheet to complete the acquisition. Closing the acquisition will be subject to final due diligence and a binding purchase agreement.

The Georgia LOI Cancelled

PHM was unable to reach an agreement on the final terms of the purchase agreement with the Georgia Company, particularly with respect to issues of indemnification.

Summary of Active LOIs

The table below summarizes the current status of PHM and the status of PHM after all LOIs are closed, Further, it summarizes the breakdown of the revenues and Adjusted EBITDA for each acquisition and the cash needed to close the acquisition. PHM plans to use $26,798,000 to close the acquisitions announced. PHM is expected to have over $10,000,000 in cash after all LOIs have closed, with revenues of $96,500,000⁽²⁾ and Adjusted EBITDA of $19,450,000⁽²⁾.

		Annualized Revenue			Annualized Adjusted EBITDA			Cash Balance
PHM Today		$	55,000,000		$	10,500,000		$	37,000,000
PHM Post-LOIs closed		$	96,500,000		$	19,450,000		$	10,202,000
Summary of LOIs									Cash To Close
Colorado		$	16,500,000		$	4,000,000		$	11,000,000
Oklahoma & Texas		$	5,000,000		$	950,000		$	1,450,000
Tennessee		$	20,000,000		$	4,000,000		$	14,348,000
Totals		$	41,500,000		$	8,950,000		$	26,798,000

"The Tennessee deal is another large acquisition for PHM and, when closed, we will likely have reached our 2015 goal of achieving $100 million in annual revenue earlier than planned," said Michael Dalsin, Chairman of PHM. "Along with the acquisition, we plan to draw down on a line of credit to ensure we have plenty of cash for further acquisitions.

"In the coming quarters, we are poised to complete the several acquisitions announced this year, almost doubling our revenue, significantly increasing EBITDA, and perhaps most importantly, adding over 90,000 patients to our database," continued Mr. Dalsin. "After we close all executed LOIs, I expect we will have a cash balance of over $10 million and we will be generating Adjusted EBITDA of close to $20 million per year⁽¹⁾. I expect these numbers will increase once we see the results of cross selling such a large patient database."

"Considering the small size of the business in Georgia and the potential of significant trailing liabilities,' concluded Mr. Dalsin. "We have decided that the risk-reward ratio was not in our favor."

Conference Call March 18, 2015 to Review Acquisition Pipeline

PHM will host an interactive Q&A conference call at 1p.m. EST on Wednesday, March 18, 2015.

Participants from PHM will be Michael Dalsin (Chairman), Roger Greene (Vice Chairman), David Hayes (CEO) and Edward Brann (M&A Banker).

The details of the call are:

Wednesday, March 18, 2015 at 1p.m. EST

US & Canada Toll Free:

Dial In: (855) 886-8711

Meeting ID Number: 548 01 39

Financial professionals are invited to call in and ask questions. To pre-register as a qualified caller, please e-mail dwilson@myphm.com by 5 p.m. EST Tuesday, March 17^th, 2015.

About PHM

The explosive growth in the number of elderly patients in the US healthcare market is creating pressure to provide more efficient delivery systems. Healthcare providers, such as hospitals, physicians and pharmacies, are seeking partners that can offer a range of products and services that improve outcomes, reduce hospital readmissions, and help control costs. PHM fills this need by delivering a growing number of specialized products and services to achieve these goals. PHM is a positive cash flow and profitable company that serves patients with heart disease and other chronic health conditions, this operation is a platform for acquisitions and organic growth. PHM is focused on a highly fragmented and developing market of small privately-held companies servicing chronically ill patients with multiple disease states caused mainly by age and obesity. Because of the new and highly fragmented nature of the market, PHM is actively working to identify and evaluate profitable, annuity-based companies to acquire their patient databases and technical expertise at favorable prices. PHM's post acquisition organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient's services and making life easier for the patient. The expected result is growing EPS with each acquisition and growing revenue and profits from the cross selling efforts.

⁽¹⁾These Adjusted EBITDA figures are unaudited and may change subject to due diligence and closing procedures. They are intended only as an estimate of trailing twelve month Adjusted EBITDA of the combined entities and are not meant to convey forward looking information. Adjusted EBITDA is a Non-IFRS measure the Company uses as an indicator of financial health, and excludes several items which may be useful in the consideration of the financial condition of the Company, including interest expense, taxes, depreciation, amortization, stock based compensation, and owner compensation.

⁽²⁾ LOI figures are based upon management's unaudited financials of the potential acquisition targets subject to due diligence before close.

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of PHM and anticipated events or results, are assumptions based on beliefs of PHM's senior management as well as information currently available to it. While these assumptions were considered reasonable by PHM at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue operations, decline of reimbursement rates, dependence on few payors, possible new drug discoveries, a novel business model, dependence on key suppliers, granting of permits and licenses in a highly regulated business, competition, low profit market segments as well as general economic, market and business conditions, and could differ materially from what is currently expected.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release does not constitute and the subject matter hereof is not, an offer for sale or a solicitation of an offer to buy, in the United States or to any "U.S. Person" (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "1933 Act")) of any equity or other securities of PHM. The securities of PHM have not been registered under the 1933 Act and may not be offered or sold in the United States (or to a U.S. Person) absent registration under the 1933 Act or an applicable exemption from the registration requirements of the 1933 Act.